April 2013 -- Nanosonics Limited (ASX:NAN) has expanded the market reach of its ultrasound probe disinfection system, trophon EPR, via a significant increase in the number of probes that have been assessed and certified for use with the technology.
As a result of increasing demand for the trophon EPR, Nanosonics has accelerated its probe testing and certification program. The number of trophon EPR-approved probes has almost doubled (up
92%) within six months, with 219 probes added from probe manufacturers Esaote, Hitachi-Aloka, Ultrasonix and Zonare, in addition to the extensive list of approved probes from GE, Philips, Siemens, Sonosite, Toshiba, BK Medical, and Prosonic.
There are now a total of 458 approved probes and this list will continue to expand. Dr Ron Weinberger, Chief Executive Officer of Nanosonics noted "Nanosonics now has strong engineering and commercial relationships with most of the ultrasound manufacturers at senior executive levels."
Ultrasound practitioners require probe manufacturer's approval before they will deploy a new disinfection solution such as trophon EPR as unapproved use can void manufacturers' warranties, which can be very costly to users.
"As more customers move away from manual disinfection methods, compatibility with trophon EPR is becoming an increasingly important purchasing consideration for ultrasound system buyers. Also, proving chemical and process compatibility between the trophon EPR and the ultrasound system is a key sales enabler. Probe manufacturers are now indicating that they need approval for use with the trophon EPR or they will lose sales." Dr Weinberger said.
This shift in the market is further evidence that trophon EPR is emerging as the new "Standard of Care" for ultrasound probe disinfection. Probe manufacturers recognise this and have, in many cases, accelerated their efforts toward broader probe testing and approvals. Some manufacturers are currently working with Nanosonics to design new probes with features that specifically complement trophon EPR and ensure compliance with FDA regulations.
Dr Ron Weinberger CEO
Nanosonics Limited ABN 11 095 076 896 Unit 24 566 Gardeners Road, Alexandria NSW 2015 Australia
Tel: +61 2 8063 1600 Fax: +61 2 8063 1600 Email: firstname.lastname@example.org w: www.nanosonics.com.au
For more information please contact:
Ron Weinberger, CEO or McGregor Grant, CFO, on 02 8063 1600
Kyahn Williamson, Media Relations, Buchan Consulting on (03) 9866 4722
Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a
variety of markets.
Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.
For more information about Nanosonics please visit www.nanosonics.com.au